alexa Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis.
Immunology

Immunology

Journal of Clinical & Cellular Immunology

Author(s): Stewart MJ, Seow CH, Storr MA

Abstract Share this page

Abstract BACKGROUND & AIMS: The incidence of microscopic colitis and its disease burden are increasing, yet there is limited systematic information addressing the use of conventional corticosteroids and budesonide in microscopic colitis. We performed a systematic review and meta-analysis on the short- and long-term efficacy of corticosteroids in treatment of microscopic colitis. METHODS: Randomized controlled trials that met predetermined selection criteria were included. Articles were identified through MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, proceedings of major gastroenterology meetings, and reference lists of trials and review articles. RESULTS: Eight randomized trials were identified. A total of 248 patients were randomized to corticosteroid versus placebo. The intervention was budesonide in 7 trials and prednisolone in 1 trial. Budesonide was significantly more effective than placebo for short-term clinical response (risk ratio [RR], 3.07; 95\% confidence interval [CI], 2.06-4.57) and long-term clinical response (RR, 3.22; 95\% CI, 1.05-9.89). Prednisolone was not superior to placebo for short-term clinical response (RR, 2.00; 95\% CI, 0.38-10.58). Histologic improvement was seen with both short- and long-term budesonide (RR, 3.76; 95\% CI, 2.00-7.06, and RR, 2.50; 95\% CI, 1.25-4.98, respectively). Symptom relapse occurred in 46\%-80\% of patients within 6 months of treatment cessation. Withdrawal because of adverse effects occurred in 4.4\% of patients, with no difference between study groups (P = .55). CONCLUSIONS: Both short- and long-term treatment with budesonide is effective and well-tolerated for microscopic colitis. However, the rate of symptom relapse once budesonide is discontinued is high. Further studies are needed to determine optimal treatment duration, dose, and withdrawal procedure. Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved. This article was published in Clin Gastroenterol Hepatol and referenced in Journal of Clinical & Cellular Immunology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords